137 related articles for article (PubMed ID: 25716096)
1. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.
Valentini V; van Stiphout RG; Lammering G; Gambacorta MA; Barba MC; Bebenek M; Bonnetain F; Bosset JF; Bujko K; Cionini L; Gerard JP; Rödel C; Sainato A; Sauer R; Minsky BD; Collette L; Lambin P
Radiother Oncol; 2015 Mar; 114(3):302-9. PubMed ID: 25716096
[TBL] [Abstract][Full Text] [Related]
2. pCR and 2-Year Disease-Free Survival: A Combination of the Two Endpoints as a New Classification for Locally Advanced Rectal Cancer Patients-An Updated Pooled Analysis of Eleven International Randomized Trials.
Gambacorta MA; Chiloiro G; Masciocchi C; Mariani S; Romano A; Gonnelli A; Gerard JP; Ngan S; Rödel C; Bujko K; Glynne-Jones R; van Soest J; Dekker A; Damiani A; Valentini V
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370819
[TBL] [Abstract][Full Text] [Related]
3. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.
Valentini V; van Stiphout RG; Lammering G; Gambacorta MA; Barba MC; Bebenek M; Bonnetain F; Bosset JF; Bujko K; Cionini L; Gerard JP; Rödel C; Sainato A; Sauer R; Minsky BD; Collette L; Lambin P
J Clin Oncol; 2011 Aug; 29(23):3163-72. PubMed ID: 21747092
[TBL] [Abstract][Full Text] [Related]
4. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
Gunderson LL; Sargent DJ; Tepper JE; Wolmark N; O'Connell MJ; Begovic M; Allmer C; Colangelo L; Smalley SR; Haller DG; Martenson JA; Mayer RJ; Rich TA; Ajani JA; MacDonald JS; Willett CG; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1785-96. PubMed ID: 15067027
[TBL] [Abstract][Full Text] [Related]
5. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
6. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
7. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
[TBL] [Abstract][Full Text] [Related]
8. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
Das P; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Janjan NA; Delclos ME; Krishnan S; Levy LB; Ellis LM; Crane CH
Am J Clin Oncol; 2006 Jun; 29(3):219-24. PubMed ID: 16755173
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
11. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
12. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
13. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
14. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
[TBL] [Abstract][Full Text] [Related]
15. Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer.
Manzini G; Ettrich TJ; Kremer M; Kornmann M; Henne-Bruns D; Eikema DA; Schlattmann P; de Wreede LC
BMC Med Res Methodol; 2018 Feb; 18(1):23. PubMed ID: 29439652
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
17. Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma.
Tay RY; Jamnagerwalla M; Steel M; Wong HL; McKendrick JJ; Faragher I; Kosmider S; Hastie I; Desai J; Tacey M; Gibbs P; Wong R
Clin Colorectal Cancer; 2017 Jun; 16(2):e45-e54. PubMed ID: 27825672
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant study end points in rectal cancer.
Fernandez-Martos C; Guerrero A; Minsky B
Recent Results Cancer Res; 2012; 196():3-19. PubMed ID: 23129363
[TBL] [Abstract][Full Text] [Related]
19. Comparative survival effectiveness between pre-operative and postoperative chemoradiotherapy for locally advanced rectal cancer: a retrospective study in Phramongkutklao Hospital.
Park P
J Med Assoc Thai; 2014 Feb; 97 Suppl 2():S1-8. PubMed ID: 25518168
[TBL] [Abstract][Full Text] [Related]
20. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
